GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Total Assets

BridgeBio Pharma (FRA:2CL) Total Assets : €781.4 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Total Assets?

BridgeBio Pharma's Total Assets for the quarter that ended in Mar. 2024 was €781.4 Mil.

During the past 12 months, BridgeBio Pharma's average Total Assets Growth Rate was 145.30% per year. During the past 3 years, the average Total Assets Growth Rate was 4.90% per year. During the past 5 years, the average Total Assets Growth Rate was 29.60% per year.

During the past 7 years, BridgeBio Pharma's highest 3-Year average Total Assets Growth Rate was 151.70%. The lowest was 4.90%. And the median was 51.80%.

Total Assets is connected with ROA %. BridgeBio Pharma's annualized ROA % for the quarter that ended in Mar. 2024 was -20.21%. Total Assets is also linked to Revenue through Asset Turnover. BridgeBio Pharma's Asset Turnover for the quarter that ended in Mar. 2024 was 0.30.

BridgeBio Pharma Total Assets Historical Data

The historical data trend for BridgeBio Pharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Total Assets Chart

BridgeBio Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial 568.51 578.35 896.32 588.15 501.03

BridgeBio Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 584.39 464.88 613.74 501.03 781.39

BridgeBio Pharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BridgeBio Pharma's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=-1231.105+1732.135
=501.0

BridgeBio Pharma's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets=Total Equity (Q: Mar. 2024 )+Total Liabilities (Q: Mar. 2024 )
=-953.909+1735.296
=781.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BridgeBio Pharma  (FRA:2CL) Total Assets Explanation

Total Assets is connected with ROA %.

BridgeBio Pharma's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %=Net Income (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=-129.596/( (501.03+781.386)/ 2 )
=-129.596/641.208
=-20.21 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BridgeBio Pharma's Asset Turnover for the quarter that ended in Mar. 2024 is

Asset Turnover
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=194.23/( (501.03+781.386)/ 2 )
=194.23/641.208
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BridgeBio Pharma Total Assets Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (FRA:2CL) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (FRA:2CL) » Definitions » Total Assets
Comparable Companies
CERE MRTX PCVX HALO ACAD IMVT IMGN INSM ASND BPMC OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
BBIO:USA
Address
3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
Website
https://www.bridgebio.com
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

BridgeBio Pharma (FRA:2CL) Headlines

No Headlines